Live
FierceBiotechRare Disease Research, myTomorrows team up to help patients access trialsFierceBiotechAligos sells China rights to HBV drug to hepatology player Amoytop in $445M dealFierceBiotechPfizer–backed Storm blows into $56M series C, launches phase 2 sarcoma trialFierceBiotechJohnson & Johnson hands back failed eye disease gene therapy to MeiraGTxFierceBiotech'Absent or trivial' effects: Anti-amyloid Alzheimer's drugs called into question once againThermo FisherThermo Fisher Scientific (TMO) Earnings Expected to Grow: Should You Buy? - Yahoo FinancePromega BlogStolen Chloroplasts and the Chrysalis of Complex LifeIlluminaDRAGEN v4.5 supports Illumina's new TruPath Genome and 5-base assays, drives insights across germline, oncology, and multiomic workflows - PR NewswireLonza NewsKeyBanc reiterates Lonza stock rating on strong modality positioning By Investing.com - Investing.com CanadaBioWorldPerha Pharmaceuticals identifies new adenosine A3 receptor antagonistsBioWorldCogent Biosciences identifies new JAK2 V617F inhibitorsBioWorldCorbus Pharmaceuticals synthesizes new cannabinoid CB1 receptor antagonists or inverse agonists
FierceBiotech Apr 16, 2026

Johnson & Johnson hands back failed eye disease gene therapy to MeiraGTx

Johnson & Johnson hands back failed eye disease gene therapy to MeiraGTx

Original
Body unavailable. Use the original source.